Skip to Content

Adynovate Approval History

FDA Approved: Yes (First approved November 13, 2015)
Brand name: Adynovate
Generic name: antihemophilic factor (recombinant) pegylated
Company: Baxalta Incorporated
Treatment for: Hemophilia A

Adynovate (antihemophilic factor (recombinant) pegylated) is a human antihemophilic factor indicated for the control and prevention of bleeding episodes in patients with hemophilia A.

Development History and FDA Approval Process for Adynovate

DateArticle
Dec 27, 2016Approval Shire Announces FDA Approval of Adynovate [Antihemophilic Factor (Recombinant), PEGylated] for Use in Children and Surgical Settings
Nov 13, 2015Approval FDA Approves Adynovate Modified Antihemophilic Factor for Hemophilia A

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide